| Followers | 57 |
| Posts | 765 |
| Boards Moderated | 0 |
| Alias Born | 07/26/2017 |
Tuesday, October 27, 2020 3:19:52 PM
ENZ* would be great fit for Eli Lilly to pair with
Recent LLY News
- Lilly Reports Strong Phase 3 Results for Retevmo in Early-Stage Lung Cancer (LLY) • IH Market News • 06/01/2026 09:37:01 AM
- Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer • PR Newswire (US) • 05/31/2026 12:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2026 07:02:20 PM
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care • PR Newswire (US) • 05/28/2026 05:00:00 PM
- Eli Lilly shares edge higher after CVS expands coverage for Zepbound obesity drug (LLY) • IH Market News • 05/28/2026 12:50:11 PM
- Foundayo and Zepbound now covered for millions of Americans • PR Newswire (US) • 05/28/2026 10:45:00 AM
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference • PR Newswire (US) • 05/27/2026 03:15:00 PM
- Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine • GlobeNewswire Inc. • 05/27/2026 12:45:00 PM
- Lilly announces three acquisitions to build infectious disease portfolio • PR Newswire (US) • 05/26/2026 10:45:00 AM
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia • PR Newswire (US) • 05/25/2026 12:45:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 06:05:43 PM
- Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting • PR Newswire (US) • 05/21/2026 09:00:00 PM
- Eli Lilly shares rise after strong late-stage obesity drug trial results (LLY) • IH Market News • 05/21/2026 12:49:05 PM
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial • PR Newswire (US) • 05/21/2026 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:22:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:19:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:18:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:17:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:16:28 PM
- Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference • PR Newswire (US) • 05/18/2026 02:00:00 PM
- Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth • PR Newswire (US) • 05/16/2026 03:00:00 PM
- Lilly and UNICEF collaborate to give millions of children a healthier start • PR Newswire (US) • 05/14/2026 11:00:00 AM
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials • PR Newswire (US) • 05/12/2026 10:01:00 PM
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries • PR Newswire (US) • 05/12/2026 04:00:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/11/2026 08:30:32 PM
